RxDoctor Payments DataLook up a doctor →

Craig Sabre, MD

Neuromusculoskeletal Medicine & OMM · Nazareth, PANPI 1174586689

Payments from drug & device makers

$12,617in general payments, 2019–2025

Across 657 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$12,600100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,030
Medicare patients
144
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$48,316
EliquisApixaban31$30,791
OzempicSemaglutide23$21,721
XareltoRivaroxaban25$20,818
FarxigaDapagliflozin Propanediol17$19,694
Synjardy XrEmpagliflozin/Metformin Hcl14$18,753
TrulicityDulaglutide13$14,911
Soliqua 100-33Insulin Glargine/Lixisenatide17$13,882
MounjaroTirzepatide13$13,251
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$5,758
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm17$4,187
ZenpepLipase/Protease/Amylase11$3,764
SynthroidLevothyroxine Sodium17$1,919
Atorvastatin Calcium149$1,638
Gabapentin93$1,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$2,072$67,06859 claims
PfizerEliquis$349$30,79131 claims
Lilly USA, LLCTrulicity, Mounjaro$1,142$28,16226 claims
Novo NordiskOzempic$1,709$21,72123 claims
AstraZenecaFarxiga$2,121$19,69417 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$163$13,88217 claims
AbbVieSynthroid$1,699$1,91917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other neuromusculoskeletal medicine & omm in Nazareth

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →